세계의 방사성 리간드 요법(RLT) 시장 : 제품별, 표적별, 적응증별, 최종사용자별, 지역별 - 예측(-2035년)

The global radioligand therapy market is projected to reach USD 10.91 billion by 2035 from an estimated USD 3.15 billion in 2025, at a CAGR of 13.2% during the forecast period.

The growth of the radioligand therapy market is majorly driven by increasing approvals and label expansions of RLT products, manufacturing scale-up, particularly for Lu-177 supply, rising adoption of PSMA and SSTR PET imaging for patient selection, and expanding reimbursement coverage supporting broader patient access.

By target, the prostate-specific membrane antigen segment accounted for the largest market share in 2024.

Based on target, the market is categorized into Prostate-Specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR), and other targets. The Prostate-Specific Membrane Antigen (PSMA) segment accounted for the largest share of the market in 2024. The large share of this segment is attributed to its high expression in prostate cancer cells and its minimal presence in normal tissues. This makes PSMA an ideal biomarker for precision oncology, enabling accurate patient selection and effective therapy delivery. The success of PSMA-targeted treatments, such as Pluvicto (lutetium-177 vipivotide tetraxetan), has reinforced its dominance, particularly in metastatic castration-resistant prostate cancer (mCRPC).

By product, the Lutetium-177 vipivotide tetraxetan segment accounted for the largest share of the market in 2024.

By product, the market is segmented into Lutetium-177 Vipivotide Tetraxetan, Lutetium-177 Dotatate, Radium-223 Dichloride, [LU-177]-PNT2002, 225AC-PSMA-617, FPI-2265/ 225 AC PSMA - I&T, I-131-1095, TLX591 (177LU Rosopatamab Tetraxetan), Alphamedix (212PB-DOTAMTATE), 67CU-SAR-BISPSMA, and other products. In 2024, the lutetium-177 vipivotide tetraxetan segment accounted for the largest share of the market. Developed and commercialized by Novartis, Lutetium-177 vipivotide tetraxetan (Pluvicto) targets Prostate-Specific Membrane Antigen (PSMA), a protein highly expressed in prostate cancer cells, making it a precision therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). Since its FDA and EMA approvals, the therapy has become widely adopted due to its ability to extend survival and improve quality of life in patients with limited treatment options. Its use of lutetium-177 enables targeted beta radiation delivery, sparing surrounding healthy tissues while maximizing tumor control.

By region, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period.

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to grow at the highest CAGR during the forecast period. The key factors contributing to market growth include the rising cancer incidence, improvements in healthcare infrastructure, and increasing awareness of precision oncology solutions. Countries such as China, Japan, South Korea, India, and Australia are witnessing the growing adoption of nuclear medicine, which is supported by expanding diagnostic capabilities and investments in theragnostic. Governments & private institutions are actively investing in isotope production facilities, addressing long-standing supply challenges for key isotopes like lutetium-177 and actinium-225, essential for commercialized and pipeline RLT products. Regulatory authorities in the region also show greater receptivity to radiopharmaceutical approvals, creating a favourable environment for clinical development and faster patient access.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side- 30%
• By Designation: Managers- 45%, CXO and Directors- 30%, and Executives- 25%
• By Region: North America- 30%, Europe- 30%, Asia Pacific- 30%, Latin America- 5%, and the Middle East & Africa- 5%

Key Companies

The key players in the radioligand therapy market include Novartis AG (Switzerland), Bayer AG (Germany), Curium US LLC (US), Eli Lilly and Company (US), AstraZeneca plc (UK), Progenics Pharmaceuticals, Inc. (US), Ariceum Therapeutics GmbH (Germany), Telix Pharmaceuticals Limited (Australia), ITM Isotope Technologies Munich SE (Germany), Convergent Therapeutics, Inc. (US), Orano Med SAS (France), Actinium Pharmaceuticals, Inc. (US), Perspective Therapeutics, Inc. (US), Clarity Pharmaceuticals Ltd. (Australia), and Radiopharm Theranostics Ltd. (Australia), among others.

Research Coverage

This research report categorizes the radioligand therapy market, by product [Lutetium-177 vipivotide tetraxetan, LUTETIUM-177 DOTATATE, Radium-223 dichloride, (LU-177)-PNT2002, 225AC-PSMA-617, FPI-2265/ 225 AC PSMA - I&T, I-131-1095, TLX591 (177LU ROSOPATAMAB TETRAXETAN), ALPHAMEDIX (212PB-DOTAMTATE), 67CU-SAR-BISPSMA, and other products), target (PSMA, SSTR, and other targets), indication (prostate cancer, neuroendocrine tumors, and other indications), and end user (tertiary care academic/comprehensive cancer centers, specialized nuclear medicine centers, and other end user), and region (North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa).

The report's scope covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the radioligand therapy market. A thorough analysis of the key industry players has provided insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements: new approvals/launches, collaborations, acquisitions, and recent developments associated with the radioligand therapy market.

Reasons to buy this report

The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the radioligand therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (increasing approvals and label expansions of RLT products, manufacturing scale-up, particularly for Lu-177 supply, the rising adoption of PSMA and SSTR PET imaging for patient selection. Expanding reimbursement coverage supporting broader patient access), restraints (Isotope scarcity for Lu-177 and Ac-225 creating supply bottlenecks, complex regulatory requirements for handling & licensing radioactive materials, logistical hurdles & half-life constraints limiting distribution), opportunities [advancements of alpha therapies (Ac-225, Pb-212) with strong clinical potential, expansion into earlier-line and adjuvant use, broadening eligible populations, combination regimens with immuno-oncology, PARP inhibitors, and other targeted agents), and challenges (reactor outages and geopolitical risks impacting isotope production & supply chains and the growing competition from alternative modalities such as ADCs and bispecific antibodies)
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the radioligand therapy market
• Market Development: Comprehensive information about lucrative markets across varied regions
• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the radioligand therapy market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment & funding activities, brand/product comparative analysis, and vendor valuation & financial metrics of the radioligand therapy market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Objectives of secondary research
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Breakdown of primaries
    • 2.1.2.2 Key objectives of primary research
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 GLOBAL MARKET ESTIMATION
    • 2.2.1.1 Company revenue analysis (Bottom-up approach)
    • 2.2.1.2 Revenue share analysis
    • 2.2.1.3 MnM repository analysis
    • 2.2.1.4 Primary interviews
  • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
  • 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
• 2.3 GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

• 3.1 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS
  • 3.1.1 BIOTECH STARTUPS AND INNOVATIVE COMPANIES
  • 3.1.2 ESTABLISHED MARKET LEADERS
  • 3.1.3 CDMOS AND CROS

4 PREMIUM INSIGHTS

• 4.1 RADIOLIGAND THERAPY MARKET OVERVIEW
• 4.2 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT AND COUNTRY, 2025
• 4.3 RADIOLIGAND THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 RADIOLIGAND THERAPY MARKET: EMERGING VS. DEVELOPED MARKETS
• 4.5 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
• 4.6 EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFT
• 4.7 VC/PRIVATE EQUITY INVESTMENT TRENDS AND STARTUP LANDSCAPE
• 4.8 REGULATORY POLICY INITIATIVES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing approvals and label expansion of RLT products
    • 5.2.1.2 Manufacturing scale-up of Lu-177
    • 5.2.1.3 Rising adoption of prostate-specific membrane antigen and somatostatin receptor PET imaging
    • 5.2.1.4 Expanding reimbursement coverage
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Isotope supply scarcity
    • 5.2.2.2 Stringent regulatory requirements
    • 5.2.2.3 Logistical hurdles and half-life constraints
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Advancements in alpha therapies
    • 5.2.3.2 Expansion of radioligand therapy into earlier-line and adjuvant settings
    • 5.2.3.3 Combination regimens integrating radioligand therapy
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Reactor outages and geopolitical risks
    • 5.2.4.2 Growing competition from alternative modalities
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 INDICATIVE PRICING ANALYSIS, BY KEY PLAYER, 2024
  • 5.4.2 INDICATIVE PRICING ANALYSIS, BY REGION
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 ECOSYSTEM ANALYSIS
• 5.7 INVESTMENT AND FUNDING SCENARIO
• 5.8 TECHNOLOGY ANALYSIS
  • 5.8.1 KEY TECHNOLOGIES
    • 5.8.1.1 Beta-emitting therapeutic radionuclides
    • 5.8.1.2 Alpha-emitting therapeutic radionuclides
    • 5.8.1.3 Targeting ligands
    • 5.8.1.4 Monoclonal antibody-directed radiotherapeutics
  • 5.8.2 COMPLEMENTARY TECHNOLOGIES
    • 5.8.2.1 SPECT/CT and PET/CT
    • 5.8.2.2 Alternative isotopes
  • 5.8.3 ADJACENT TECHNOLOGIES
    • 5.8.3.1 Antibody drug conjugates
    • 5.8.3.2 Bispecific antibodies
• 5.9 KEY CONFERENCES AND EVENTS, 2025-2027
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY ANALYSIS
  • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.11 PORTER'S FIVE FORCES ANALYSIS
  • 5.11.1 BARGAINING POWER OF SUPPLIERS
  • 5.11.2 BARGAINING POWER OF BUYERS
  • 5.11.3 THREAT OF NEW ENTRANTS
  • 5.11.4 THREAT OF SUBSTITUTES
  • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.12 KEY STAKEHOLDERS AND BUYING PROCESS
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 BUYING CRITERIA
• 5.13 MACROECONOMICS INDICATORS
  • 5.13.1 HEALTHCARE EXPENDITURE TRENDS
  • 5.13.2 GLOBAL CANCER BURDEN
• 5.14 PIPELINE ANALYSIS
• 5.15 UNMET NEEDS AND WHITE SPACES
• 5.16 IMPACT OF AI/GEN AI ON RADIOLIGAND THERAPY MARKET
  • 5.16.1 INTRODUCTION
  • 5.16.2 MARKET POTENTIAL OF AI IN RADIOLIGAND THERAPY APPLICATIONS
  • 5.16.3 AI USE CASES
• 5.17 IMPACT OF 2025 US TARIFF
  • 5.17.1 INTRODUCTION
  • 5.17.2 KEY TARIFF RATES
  • 5.17.3 PRICE IMPACT ANALYSIS
  • 5.17.4 IMPACT ON COUNTRY/REGION
    • 5.17.4.1 US
    • 5.17.4.2 Europe
    • 5.17.4.3 Asia Pacific
    • 5.17.4.4 Rest of the World
  • 5.17.5 IMPACT ON MANUFACTURING INDUSTRY

6 RADIOLIGAND THERAPY MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 LUTETIUM 177 VIPIVOTIDE TETRAXETAN
  • 6.2.1 BROADER REGULATORY ACCEPTANCE AND EXPANDING PAYER COVERAGE TO AID GROWTH
• 6.3 LUTETIUM-177 DOTATATE
  • 6.3.1 INCREASING RECOGNITION OF LUTETIUM-177 DOTATATE IN TREATING GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS TO BOOST MARKET
• 6.4 RADIUM-223 DICHLORIDE
  • 6.4.1 INCREASING ADOPTION OF RADIUM-223 DICHLORIDE IN EMERGING MARKETS TO STIMULATE GROWTH
• 6.5 LU-177 PNT2002
  • 6.5.1 STRONG PHASE III CLINICAL VALIDATION AND STRATEGIC COMMERCIALIZATION PARTNERSHIPS TO SPUR GROWH
• 6.6 225AC-PSMA-617
  • 6.6.1 POTENT THERAPEUTIC PROFILE AND EXPANDING CLINICAL VALIDATION TO BOLSTER GROWTH
• 6.7 FPI-2265
  • 6.7.1 EARLY RESPONSE DATA AND SAFETY REASSURANCE TO AMPLIFY GROWTH
• 6.8 I-131-1095
  • 6.8.1 FAVORABLE DOSIMETRY AND SAFETY PROFILES TO SUSTAIN GROWTH
• 6.9 TLX591
  • 6.9.1 SIMPLIFIED DOSING REGIMEN AND FAVORABLE TOLERABILITY TO DRIVE MARKET
• 6.10 ALPHAMEDIX ( 212PB-DOTAMTATE)
  • 6.10.1 ROBUST EARLY-PHASE EFFICACY AND STRONG COMMERCIALIZATION TO SUPPORT GROWTH
• 6.11 67CU-SAR-BISPSMA
  • 6.11.1 ENHANCED LESION UPTAKE & RETENTION AND FAVORABLE TOLERABILITY PROFILE TO FOSTER GROWTH
• 6.12 OTHER PRODUCTS

7 RADIOLIGAND THERAPY MARKET, BY TARGET

• 7.1 INTRODUCTION
• 7.2 PROSTATE-SPECIFIC MEMBRANE ANTIGEN
  • 7.2.1 STRONG BIOLOGICAL RATIONALE, ROBUST CLINICAL OUTCOMES, AND RAPID SCALING OF GLOBAL SUPPLY CHAINS TO PROMOTE GROWTH
• 7.3 SOMATOSTATIN RECEPTOR
  • 7.3.1 PROVEN EFFICACY IN TREATING NEUROENDOCRINE TUMORS TO EXPEDITE GROWTH
• 7.4 OTHER TARGETS

8 RADIOLIGAND THERAPY MARKET, BY INDICATION

• 8.1 INTRODUCTION
• 8.2 PROSTATE CANCER
  • 8.2.1 EXPANDING TREATMENT POPULATIONS AND CLINICAL VALIDATION TO ENCOURAGE GROWTH
• 8.3 NEUROENDOCRINE TUMORS
  • 8.3.1 REGULATORY ADVANCEMENTS AND STRATEGIC INDUSTRY MOVES TO FACILITATE GROWTH
• 8.4 OTHER INDICATIONS

9 RADIOLIGAND THERAPY MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS
  • 9.2.1 ADVANCED TREATMENT DELIVERY AND CLINICAL TRIAL CAPABILITIES TO CONTRIBUTE TO GROWTH
• 9.3 SPECIALIZED NUCLEAR MEDICINE CENTERS
  • 9.3.1 HIGHLY TRAINED PERSONNEL AND TARGETED FACILITIES TO ACCELERATE GROWTH
• 9.4 OTHER END USERS

10 RADIOLIGAND THERAPY MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Robust ecosystem of biotech innovation and strong academic-industry collaboration to spur growth.
  • 10.2.3 CANADA
    • 10.2.3.1 Growing clinical trial momentum to drive market
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Strong clinical advancements and active industry partnerships to foster growth.
  • 10.3.3 UK
    • 10.3.3.1 Growing efforts for decentralized access and innovations to boost market
  • 10.3.4 FRANCE
    • 10.3.4.1 Strong nuclear medicine manufacturing and isotope supply foundation to bolster growth
  • 10.3.5 ITALY
    • 10.3.5.1 Rising preclinical exploration and early discovery stages to stimulate growth
  • 10.3.6 SPAIN
    • 10.3.6.1 Established nuclear-medicine departments and authorized radiopharmacy frameworks to aid growth
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 CHINA
    • 10.4.2.1 Favorable regulatory reforms and expanding hospital-based nuclear medicine capabilities to amplify growth
  • 10.4.3 JAPAN
    • 10.4.3.1 Academic excellence, manufacturing expansion, and supportive regulation to contribute to growth
  • 10.4.4 INDIA
    • 10.4.4.1 Lower trial costs and skilled medical professionals to accelerate growth
  • 10.4.5 SOUTH KOREA
    • 10.4.5.1 Growing emphasis on nuclear medicine innovation to propel market
  • 10.4.6 AUSTRALIA
    • 10.4.6.1 Need to maintain high standards of quality, compliance, and innovation to facilitate growth
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Favorable educational initiatives and expanding biopharma infrastructure to promote growth
  • 10.5.3 MEXICO
    • 10.5.3.1 Growing cyclotron capacity to fuel market
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST
  • 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 10.6.2 GCC COUNTRIES
  • 10.6.3 SAUDI ARABIA
    • 10.6.3.1 Growing initiatives for healthcare and life sciences sectors to drive market
  • 10.6.4 UAE
    • 10.6.4.1 Emerging biotechnology sector to intensify growth
  • 10.6.5 REST OF GCC COUNTRIES
  • 10.6.6 REST OF MIDDLE EAST
• 10.7 AFRICA
  • 10.7.1 ENHANCED CLINICAL TRIAL ECOSYSTEM AND REGULATORY REFORMS TO AID GROWTH
  • 10.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
• 11.3 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
• 11.4 REVENUE ANALYSIS, 2028-2030
• 11.5 MARKET SHARE ANALYSIS, 2030
• 11.6 COMPANY VALUATION AND FINANCIAL METRICS
• 11.7 BRAND/PRODUCT COMPARISON
• 11.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 11.8.1 STARS
  • 11.8.2 EMERGING LEADERS
  • 11.8.3 PERVASIVE PLAYERS
  • 11.8.4 PARTICIPANTS
  • 11.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 11.8.5.1 Region footprint
    • 11.8.5.2 Target footprint
    • 11.8.5.3 Indication footprint
• 11.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 11.9.1 PROGRESSIVE COMPANIES
  • 11.9.2 RESPONSIVE COMPANIES
  • 11.9.3 DYNAMIC COMPANIES
  • 11.9.4 STARTING BLOCKS
  • 11.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 11.9.5.1 Detailed list of key startups/SMEs
    • 11.9.5.2 Competitive benchmarking of key startups/SMEs
• 11.10 COMPETITIVE SCENARIO
  • 11.10.1 PRODUCT LAUNCHES AND APPROVALS
  • 11.10.2 DEALS
  • 11.10.3 EXPANSIONS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 NOVARTIS AG
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Products in pipeline
    • 12.1.1.4 Recent developments
      • 12.1.1.4.1 Product launches and approvals
      • 12.1.1.4.2 Deals
      • 12.1.1.4.3 Expansions
    • 12.1.1.5 MnM view
      • 12.1.1.5.1 Key strengths
      • 12.1.1.5.2 Strategic choices
      • 12.1.1.5.3 Weaknesses and competitive threats
  • 12.1.2 BAYER AG
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
      • 12.1.2.2.1 Deals
      • 12.1.2.2.2 Other developments
    • 12.1.2.3 MnM view
      • 12.1.2.3.1 Key strengths
      • 12.1.2.3.2 Strategic choices
      • 12.1.2.3.3 Weaknesses and competitive threats
  • 12.1.3 CURIUM US LLC
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products in pipeline
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Deals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 ELI LILLY AND COMPANY
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products in pipeline
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product launches and approvals
      • 12.1.4.3.2 Deals
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Key strengths
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses and competitive threats
  • 12.1.5 ASTRAZENECA
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products in pipeline
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Deals
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strengths
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses and competitive threats
  • 12.1.6 PROGENICS PHARMACEUTICALS INC. (LANTHEUS)
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products in pipeline
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Deals
  • 12.1.7 ARICEUM THERAPEUTICS
    • 12.1.7.1 Products in pipeline
    • 12.1.7.2 Recent developments
      • 12.1.7.2.1 Deals
  • 12.1.8 TELIX PHARMACEUTICALS
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products in pipeline
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Deals
      • 12.1.8.3.2 Expansions
      • 12.1.8.3.3 Other developments
  • 12.1.9 ITM ISOTOPE TECHNOLOGIES
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Deals
      • 12.1.9.3.2 Expansions
  • 12.1.10 CONVERGENT THERAPEUTICS, INC.
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products in pipeline
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Product launches and approvals
      • 12.1.10.3.2 Deals
  • 12.1.11 ORANO SA
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products in pipeline
    • 12.1.11.3 Recent developments
      • 12.1.11.3.1 Deals
      • 12.1.11.3.2 Expansions
  • 12.1.12 ACTINIUM PHARMACEUTICALS, INC.
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products in pipeline
    • 12.1.12.3 Recent developments
      • 12.1.12.3.1 Product launches and approvals
      • 12.1.12.3.2 Deals
  • 12.1.13 PERSPECTIVE THERAPEUTICS, INC.
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products in pipeline
    • 12.1.13.3 Recent developments
      • 12.1.13.3.1 Deals
  • 12.1.14 CLARITY PHARMACEUTICALS
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products in pipeline
    • 12.1.14.3 Recent developments
      • 12.1.14.3.1 Deals
      • 12.1.14.3.2 Other developments
  • 12.1.15 RADIOPHARM THERANOSTICS LTD.
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products in pipeline
    • 12.1.15.3 Recent developments
      • 12.1.15.3.1 Deals
• 12.2 OTHER PLAYERS
  • 12.2.1 ALPHA 9 ONCOLOGY
  • 12.2.2 RATIO THERAPEUTICS
  • 12.2.3 NORIA THERAPEUTICS
  • 12.2.4 PRECIRIX
  • 12.2.5 SOFIE
  • 12.2.6 ECKERT & ZIEGLER RADIOPHARMA
  • 12.2.7 NORTHSTAR MEDICAL RADIOISOTOPES, LLC
  • 12.2.8 IRE- IRE ELIT
  • 12.2.9 BWXT MEDICAL LTD.
  • 12.2.10 NTP RADIOISOTOPES

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS